Indoco Remedies Reports Q3 FY25 Loss

  Published 1 year ago

Indoco Remedies, a pharmaceutical company manufacturing allopurinol (generic for Zyloprim) and APIs, reported a net loss of Rs 10.23 crore in Q3 FY25, a significant drop from the profit in Q3 FY24. Revenue also decreased by 18.61%.

  • Allopurinol treats high uric acid levels.
  • Indoco produces both APIs & formulations.
  • Q3 FY25 revenue was Rs 364.91 crore.

You might like these

Sigachi Industries Expands API Manufacturing in India

Russian Oil Freight Rates Drop Amid EU Price Cap Debate

Oil India Wins First Domestic Potash Block

Divis Labs Posts Strong YoY Growth

Jio BlackRock Raises $2.1B in Mutual Fund Offerings

Indus Towers Expands in Africa

Meesho Files IPO, Aims to Raise $497M

News that matters the most ⚡